Portola Pharmaceuticals Inc

Portola Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development and commercialization of novel therapeutics in the field of thrombosis and other hematologic disorders. Our mission is to improve the lives of patients by advancing the science of blood clotting and developing innovative treatments that address unmet medical needs. Our flagship product, Andexxa, is the first and only antidote for Factor Xa inhibitors, which are widely used in the treatment of atrial fibrillation and venous thromboembolism. We are also developing a pipeline of other novel therapies, including cerdulatinib for the treatment of hematologic cancers and other immune-related diseases. With a team of experienced scientists and clinicians, we are committed to delivering innovative solutions that improve patient outcomes and transform the standard of care in thrombosis and other hematologic disorders.